Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brasschaat, Belgium
  • Research Site Liège, Belgium
  • Research Site Overpelt, Belgium
  • Research Site Wilrijk, Belgium
View all 64 locations
View Trial Details
Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

NCT01317004

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Ancona, AN, Italy
  • Novartis Investigative Site Ponderano, BI, Italy
  • Novartis Investigative Site Caltanissetta, CL, Italy
  • Novartis Investigative Site Cuneo, CN, Italy
View all 17 locations
View Trial Details
Completed

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Fraiture En Condroz, Belgium
  • GSK Investigational Site Hamburg, Free and Hanseatic City of Hamburg, Germany
  • GSK Investigational Site Hamburg, Free and Hanseatic City of Hamburg, Germany
View Trial Details
Completed

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

NCT00228163

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Investigational Site Number 16 Calgary, Canada
  • Investigational Site Number 10 Halifax, Canada
  • Investigational Site Number 15 London, Canada
  • Investigational Site Number 12 Montreal, Canada
View all 16 locations
View Trial Details

Related conditions